ec4f2c9f.7d4b.45fe.9064.f96e4a1e52e6
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.380
- GLYCOLYSIS+0.370
- XENOBIOTIC_METABOLISM+0.370
- PROTEIN_SECRETION+0.350
- FATTY_ACID_METABOLISM+0.340
- INTERFERON_ALPHA_RESPONSE+0.330
- MTORC1_SIGNALING+0.330
- ADIPOGENESIS+0.280
- HYPOXIA+0.280
Top 10 suppressed
- TGF_BETA_SIGNALING-0.410
- G2M_CHECKPOINT-0.360
- MITOTIC_SPINDLE-0.330
- HEDGEHOG_SIGNALING-0.320
- WNT_BETA_CATENIN_SIGNALING-0.310
- UV_RESPONSE_DN-0.290
- NOTCH_SIGNALING-0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.220
- APICAL_JUNCTION-0.190
- ANGIOGENESIS-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a8e85cdd-3770-40a0-837e-6962ec12fcf0 | — | — | 0.835 |
| 2 | 131a9973-dfc9-4897-8c19-d5c43cecba0a | — | — | 0.818 |
| 3 | ERR2208921 | — | — | 0.813 |
| 4 | TCGA-49-4488-01A-01R-1755-07 | — | cohortA1 | 0.805 |
| 5 | MBCProject_4424_T3_RNA | — | C | 0.788 |
| 6 | BS_EYYMKWB7 | subependymal giant cell astrocytoma(SEGA) | — | 0.786 |
| 7 | TCGA-05-4418-01A-01R-1206-07 | — | cohortA4 | 0.784 |
| 8 | C3N-00572 | — | cohortA1 | 0.782 |
| 9 | TCGA-BH-A0HO-01A-11R-A034-07 | — | B | 0.781 |
| 10 | SRR27320676 | — | — | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.370 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.370 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| PEROXISOME | 0.270 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.230 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |